Top 30 Drugs By Global Sales In 2024

Global Pandemic COVID-19 has turned the fate of many international pharmaceutical companies by paving way for their successful increase in sales revenues. But at the same time, number of pharmaceutical enterprises faced dramatic down in their long term selling reign as the world's priority was totally shifted towards eliminating the different variants of Coronavirus.

AdobeStock_276803150-scaled

The new year of 2023 is thus graciously welcomed as an indicator of the end of COVID-19. Now, the change in top 30 drugs by global sales in 2023 can be clearly understood by the data given below. To know about these top-selling drugs make sure you have gone through the underlying information!

Rank Drug Name Company Sales
1 Keytruda Meri & Co $24 billion
2 Comirnaty Pfizer $19 billion
3 Humira AbbVie $13.5 billion
4 Paxlovid Pfizer $13 billion
5 Eliquis BMS/Pfizer $13 billion
6 Opdivo BMS/Ono Pharmaceutical $11.5 billion
7 Dupixent Sanofi $11 billion
8 Stelara Johnson & Johnson, Mitsubishi $11 billion
9 Spikevax/Covid-19 vaccine Moderna $11 billion
10 Biktarvy Gilead $11 billion
11 Imbruvica AbbVie, Johnson & Johnson $9.8 billion
12 Trikafta/Kaftrio Vertex Pharmaceuticals $9 billion
13 Eylea Regeneron Pharmaceuticals, Bayer $8 billion
14 Darzalex Johnson & Johnson $8 billion
15 Xarelto Bayer, Johnson & Johnson $7 billion
16 REGEN-COV/Ronapreve Regeneron, Roche $7 billion
17 Gardasil 9 Merck $6.9 billion
18 Trulicity Eli Lilly $6.5 billion
19 Veklury Gilead Sciences $6.4 billion
20 Prevenar 13 Pfizer and Daewoong Pharmaceutical $6 billion
21 Tagrisso AstraZeneca $5.8 billion
22 Entyvio Takeda Pharmaceutical $5.4 billion
23 Perjeta Roche and Shugai Pharmaceutical $4.9 billion
24 Cosentyx Novartis $4.8 billion
25 Xtandi Astellas and Pfizer $4.7 billion
26  Soliris AstraZeneca & Alexion Pharmaceutical $4.3 billion
27 Enbrel Amgen and Pfizer $4 billion
28 Ibrance Pfizer $3.3 billion
29 Invega Sustenna & Invega Trinza Johnson & Johnson $2.5 billion
30 Ocrevus Roche $1.5 billion

Keytruda

Company: Merck & Co

Sales: $24 billion

Description

Keytruda is a type of immunotherapy drug used for preventing certain types of cancers such as lung cancer, breast cancer, cervical cancer and others. It is slowly infused in body through injection. Merck Corporation is the producer of this influencial drug which has generated $24 billion sales in 2023 and contributing to the total 40% of Company's pharmaceutical segment revenue.

Comirnaty

Company: Pfizer

Sales: $19 billion

Description

Comirnaty is a type of monovalent vaccine used for curing CORONAVIRUS dieses. This vaccine is adopted for individuals of age 12 and over. Under the administration of Pfizer, Comirnaty has added much to the company's overall revenue by producing sales of $36 billion in 2021, $37 billion in 2022 and $19 billion in 2023.

Humira

Company: AbbVie

Sales: $13.5 billion

Description

AbbVie is United States' top famous biomedical company known for its discoveries of innovative medicinal treatment. Among them, Humira injection pen is most popular for holding prescribed medicine. The Humira injection pen contains two dosage of liquid that prevent moderate to severe inflammatory symptoms in adults including rheumatoid arthritis and Pediatric Ulcerative Colitis. For past decade, the sudden rise of $2 billion sales in each year has been noticed which is still continued.

Paxlovid

Company: Pfizer

Sales: $13 billion

Description

Paxlovid is a type of oral dosage formed by the combination of two antiviral medications. The solution is secured by Pfizer in form of tablets, for combating new variant of Coronavirus named omicron. Its highly rapid effects have resulted in the unexpected boost to Pfizer sales revenue by surprising sales of $18.9 billion in 2022 and $13 billion in 2023.

Eliquis

Company: BMS/Pfizer

Sales: $13 billion

Description

The collaboration of two competitors BMS and Pfizer is no doubt can be seen in bright outcomes, the drug Eliquis displayed. Having been anticoagulant medication, Eliquis is effectively preventing certain types of blood clotting. Eliquis is a form of oral dosage approved by FDA, which has shown remarkable sales in recent years by uplifting the revenue of both manufacturers $9 billion and $3 billion respectively.

Opdivo

Company: BMS/Ono Pharmaceutical

Sales: $11.5 billion

Description

Opdivo is a prescribed dosage in form of injection water. It is particularly prepared to destroy the cells of kidney cancer, stomach cancer, esophageal cancer and gastric cancer. After the fluctuation in 2020, a rise in the sale of Opdivo has seen in recent two years. The estimates further show that both BMS and Ono Pharmaceutical are going to generate $11 billion revenue through Opdivo sales.

Dupixent

Company: Sanofi

Sales: $11 billion

Description

Dupixent is an injectable medication brought by Sanofi to treat the serious inflammation that may create rash, redness and itching. Approved by FDA, European Commission and dermatologists, Dupixent is now okay for children over 6 months. Along with that certain other benefits of improving sleep, reduction in skin pain and zero side effects are associated with Dupixent. This is the reason for its high demand as a result of which its revenue exceeded $11billion.

Stelara

Company: Johnson & Johnson

Sales: $11 billion

Description

Stelara was introduced in 2009 by Janssen Pharmaceuticals, to defeat the serious and painful disease of psoriasis, Crohn's disease and psoriatic arthritis. By entering the market, Stelara sales were increasing with rise of 20% seen in three consecutive years starting from 2020. Currently, this drug of Johnson & Johnson is facing a little down due to AbbVie's Humira used for same disease. However, the drug is expected to encompass the sales revenue of near $11 billion in 2023.

9.Spikevax/Covid-19 vaccine

Spikevax

Company: Moderna

Sales: $11 billion

Description

Moderna's Spikevax is a vaccine used for strengthening immune system to fight against COVID-19 infection. Moderna boosted its economy by generating near $40 billion sales revenue in just past two years. This uplifting sales has faced a slump in 2023 with reduction in Coronavirus disease. Despite falling the sales, Moderna is forecasting to secure $11 billion revenue in the running year.

Biktarvy

Company: Gilead

Sales: $11 billion

Description

Biktarvy is an antiviral fixed-dose medication, indicated for the treatment of most dreadful illness of HIV/AIDS. Study shows, that it lowers the presence of HIV in human body and help them in minimizing HIV complications. Its manufacturer Gilead has gained probably the highest revenue up till now by the sudden increase in HIV cases and also the prices of drug contributed to it. Gilead declared, its sales of Biktarvy has been increased by 20% in 2022 following the same frequency with a 1% rise in 2023 by getting $11 billion sales revenue.

Imbruvica

Company: AbbVie, Johnson & Johnson

Sales: $9.8 billion    

Description

AbbVie and Johnson & Johnson's Imbruvica is a prescribed oral dosage in form of capsules. Approved by FDA Imbruvica is indicated to be taken by adults for curing hematologic cancers and Waldenström's macroglobulinemia (WM). Having presence in over 95 countries, Imbruvica is continuously delivering fruitful outcomes for the efforts of both manufacturers by giving surprisingly sales of near $10 billion.

12.Trikafta/Kaftrio

Kaftrio

Company: Vertex Pharmaceuticals

Sales: $9 billion

Description

As the name indicates, Trikafta is the mixture of three distinct compounds tezacaftor, elexacaftor and ivacaftor. It is primarily used for cystic fibrosis, a rare genetic pulmonary disorder. When it comes to the top seller of Trikafta, global sights stood at Vertex Pharmaceuticals, who generate about $8.2 billion in 2022 by selling this drug alone. Looking ahead, Vertex Pharmaceuticals is determined to cross the figure $9 billion in 2023.

Eylea

Company: Regeneron Pharmaceuticals, Bayer

Sales: $8 billion

Description

Regeneron Pharmaceuticals and Bayer is doing constant efforts to keep the value of Eylea on same position despite the new formulas introduced by growing competitors. The effective drug of Eylea is a type of liquid medication infused in eyes through injection. Eylea is primarily indicated to treat wet age-related macular degeneration (AMD). Eylea has generated $8.9 billion sales revenue in 2021 that was dropped by 3% in 2022 with 8% billion. The same is expected for running year 2023.

Darzalex

Company: Johnson & Johnson

Sales: $8 billion

Description

Darzalex is the world's first ever drug launched for the treatment of multiple myeloma. It can be also used for treating other diseases by combination with different formulas. Darzalex is Johnson & Johnson's second most popular drug used on large scale. A positive shift was seen in sales revenue of Darzalex last year which increased from $7 billion in 2021 to $8 billion in 2022 and the same is continued for 2023.

Xarelto

Company: Bayer, Johnson & Johnson

Sales:$7 billion

Description

Xarelto by Bayer and Johnson & Johnson is an anticoagulant medication launched for intelligently treating the disease of blood clotting in adults. The drug remained an upward trajectory throughout pandemic, but the circumstances changed abruptly in the last quarter of 2022. Yet, it has the potential to stood at the area and reach $7 billion sales in 2023.

16.REGEN-COV/Ronapreve

Ronapreve

Company: Regeneron, Roche

Sales: $7 billion

Description

In 2020, U.S. Food and Drug Administration has approved REGEN-COV to be used on emergency basis for adult patients older than 12 years having positive result for COVID-19. The vaccine delivered remarkable sales in 2020 and 2021 with $7.5 billion revenue. Later, with the development of new and proper vaccines, its revenue fell from 1.14 billion euros to 1.9 billion euros.

Gardasil 9

Company: Merck & Co.

Sales: $6.9 billion

Description

Gardasil 9 is a vaccine prepared for the elimination of 9 types of Human papillomavirus HPV, common sexually transmitted diseases especially among women. It was developed by Merck & Co. in 2014 which was soon welcomed internationally; however, the rise of pandemic diverted the world's attention towards COVID-19 vaccines. But now, Gardasil 9 has backed to its position as countries are focused on preventing routine viruses. That's how, the growth of Gardasil 9 sales increased by 22% in 2022 with $6.9 billion revenue and company is ambitious to further increase this figure.

Trulicity

Company: Eli Lilly

Sales: $6.5 billion

Description

Trulicity GLP-1 agonist is an injectable medication brought by Eli Lilly for curing type-2 diabetes and normalizing blood sugar. It is one of the Eli Lilly's top drugs having high contribution in uplifting the company's overall revenue. Trulicity's sales, serve as a good indicator of this trend, which increased from $5 billion in 2020 to $7 billion in 2022. The company is expecting same for future.

Veklury

Company: Gilead Sciences

Sales: $6.4 billion

Description

Veklury is a type of COVID-19 vaccination introduced by Gilead Sciences. It was employed to be used for adults in general and children with at least age of 4 weeks in particular. Gilead Sciences' has captured international attention for its effective and affordable dose of COVID-19 vaccine. Up till now, Veklury has added up to $15 billion revenue to Gilead by its sales.

Prevenar 13

Company: Pfizer and Daewoong Pharmaceutical

Sales: $6 billion

Description

Prevenar 13 is a single-dose prefilled syringe that is injected into body for preventing pneumococcal disease in adults and children with over 5 years. Pfizer and Daewoong Pharmaceutical collaborated for manufacturing this drug, which in turn has contributed to give high revenue from past 3 years. Recently, both companies are forecasting to carry the figure of $6 billion in 2023 on part of Prevenar 13 sales.

Tagrisso

Company: AstraZeneca

Sales: $5.8 billion

Description

Tagrisso is a type of film-coated tablets particularly prepared for treating lung cancer and associated disorder. It is low in dosage, that's why most of the doctors allow patients to take it by their own whenever they feel abnormal epidermal growth. Tagrisso generated brilliant sales revenue of $5.4 billion in 2022 for AstraZeneca and the company has declared the rise in it by mentioning figure of $5.8 billion for 2023.

Entyvio

Company: Takeda Pharmaceutical

Sales: $5.4 billion

Description

Entyvio is one of the Takeda Pharmaceutical's top drugs launched in 2014. The drug is indicated for the treatment of moderate to severe ulcerative colitis or Crohn's disease. Takeda has received around $5.4 billion sales revenue from Entyvio in 2023. Its sales is further projected above $5.4 in 2023.

Perjeta

Company: Roche and Chugai Pharmaceutical

Sales: $4.9 billion

Description

Perjeta is the prime medication brought by Roche in 2012 to target the rising cases of breat cancer among women. Later with the assistance from Chugai Pharmaceutical both enterprises joined hands to work collectively, and resultantly they have seen a surprising boost in Perjeta revenue which increased from $3.9 billion to $4.9 billion in 2013.

Cosentyx

Company: Novartis

Sales: $4.8 billion

Description

Novartis approved Cosentyx by FDA in 2014 as a first ever human biologic medication for Plaque psoriasis, active psoriatic arthritis and active ankylosing spondylitis. The efficiency and demand of this drug has thus pushed its sales from all over the world, and now it is considered among world's top-selling drugs with $4.8 revenues.

Xtandi

Company: Astellas, Pfizer

Sales: $4.7 billion

Description

Based in Tokyo, Japan, Astellas is a reputable pharmaceutical company dedicated to revitalize the existing medicine formulas by innovation. In 2021, Pfizer became a partner of Astellas for the project of Xtandi capsules to resist prostate cancer. Consequently, the project became successful and generated about $4.7 billion sales revenue in 2023.

Soliris

Company: AstraZeneca and Alexion Pharmaceuticals

Sales: $4.3 billion

Description                                                                

Alexion Pharmaceutical is the original developer of Soliris, a drug for curing the disease of Paroxysmal Nocturnal Hemoglobinuria and Hemolytic Uremic Syndrome. In July 2021, AstraZeneca came to an agreement with Alexion and got up to $4.1 billion sales revenue in 2022. The owners of Soliris are estimating further increase in its existing sales with giving ratio of $4.3 billion.

Enbrel

Company: Amgen and Pfizer

Sales: $4 billion

Description

Enbrel is a type of prescribed medication available in form of injection. It is adopted for the minor symptoms or severe rheumatoid arthritis (RA) disease. However, the drug may badly affect the immune system of patient taking it. The two partners Amgen and Pfizer are still having positive estimates about the future sales revenue of $4 billion in part of Enbrel.

Ibrance

Company: Pfizer

Sales: $3.3 billion

Description

Pfizer developed a prescription medication Ibrance to treat the diseases of HR+, HER-2 and breast cancer in women and men. In 2015, Ibrance was quite popular and had good demand. However, it was later competed by Eli Lilly and Novartis with same drug. Currently, the company is generating $3.3 billion of its sales revenue by selling Ibrance.

29.Invega Sustenna and Invega Trinza

Invega Trinza

Company: Johnson & Johnson

Sales: $2.6 billion

Description

Invega Sustenna and Invega Trinza can be better defined as two faces of the same coin. It is due to their association with similar treatment of schizophrenia; first by Invega Sustenna for 6 months followed by Invega Trinza. This perfect combination is brought by Johnson & Johnson which was warmly welcomed by international pharmacies. As a result, a big rise of $2.6 billion revenue was achieved in short period.

Ocrevus

Company: Roche

Sales: $1.5 billion

Description

Roche's Ocrevus has seen applausable growth despite the growing competitors and waves of pandemic. It was launched to cure certain forms of primary progressive multiple sclerosis in adults. It shows rapid effects by slowing down symptoms of the disease. Thus, Roche is proud of this effective drug creation that has added about $1.5 billion sales revenue to its income.

Conclusion

We hope, this article demonstrated a clear picture of top 30 drugs by global sales in 2023. Research has shown, that above top 30 drugs are contributing on a larger scale to the overall revenue of their manufacturers. All these drugs are approved by U.S. Food and Drug Administration and have undergone various clinical trials to be of good quality. Was this information helpful for you? If yes! You should never miss a chance to know similar content. Just be in contact with us for knowing more.

Don't forget to share this post!

Vial Filling Machine Related Products

Vial Filling Machine Related Videos

The Best Kept Secrets About Vial Filling Machine

The ever best video how ampoule produced by the ampoule filling line

The 17 Most Misunderstood Facts About Pharmaceutical Vial Filling Machine Production Line

CONTACT US

Tell us your raw material and project budget to get quotations within 24 hours.

WhatsApp Us: +86 189 7157 0951

Invalid Email
Invalid Number
Scroll to Top